"It is unclear whether these results from immune-deficient mouse models would be similar to those of patients with metastatic cancer. In particular, it is unknown whether the patients' immune system would reduce the effectiveness of SVV-001," the study authors wrote.
Hallenbeck said the phase I trial is expected to be completed some time next year. If all goes well in that trial, testing of the virus will move on to trials designed to measure effectiveness, he said.
To learn about cancer advances made in recent years, visit the U.S. National Cancer Institute.
SOURCES: Paul Hallenbeck, Ph.D., M.S., president, founder, chief scientific officer, Neotropix, Malvern, Pa.; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Nov. 7, 2007, Journal of the National Cancer Institute